Roche announces FDA approval of Xofluza baloxavir marboxil for influenza

Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza

Roche today announced that the US Food and Drug Administration (FDA) has approved Xofluza ™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.

More From BioPortfolio on "Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza"